Lilly to buy Ventyx Biosciences for $1.2 billion in push beyond weight-loss drugs

Eli Lilly has agreed to buy Ventyx Biosciences, a San Diego-based developer of oral immune drugs, for $1.2 billion in cash, the companies said on January 7 ^[1][3]. Reuters called it the maker of Zepbound's latest push to expand beyond its blockbuster diabetes and weight-loss medicines, and Lilly's first major transaction of 2026 ^[1].

Lilly will pay $14.00 per share for all outstanding Ventyx shares ^[2][3]. The sources describe the price differently. Reuters said it represents a premium of about 2% over the stock's closing price on Wednesday ^[1]. Lilly's announcement and BioPharma Dive put the premium at roughly 62% over Ventyx's 30-day volume-weighted average trading price through January 5 ^[2][3]. The gap reflects how far the stock had already run: Ventyx shares closed 28% higher the day after media reports of the talks ^[1].

What Lilly is buying

Ventyx develops small-molecule pills, including a class of drugs called NLRP3 inhibitors that block proteins which stimulate inflammation in a range of tissues ^[2][3]. Its pipeline includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 testing for recurrent pericarditis, and VTX3232, a brain-penetrant NLRP3 inhibitor that has been studied in early-stage Parkinson's disease ^[3]. It also has two Phase 2 compounds for inflammatory bowel diseases such as Crohn's and ulcerative colitis, tamuzimod and VTX958 ^[1][3].

The strongest data cited in the coverage came in October. Ventyx reported that VTX3232 reduced a biological marker of heart disease by 64% over 12 weeks in people with obesity and cardiovascular risk factors, compared with a 3% rise among those who received a placebo ^[2]. Given alongside semaglutide, the active ingredient in Novo Nordisk's Wegovy, the combination also significantly reduced signs of liver inflammation and other cardiovascular markers ^[2].

"There is increasing evidence that inflammation is a key driver of many chronic diseases," Lilly chief scientific and product officer Daniel Skovronsky said in a statement ^[2][3]. Ventyx chief executive Raju Mohan said Lilly has "unparalleled resources, a passion for innovative oral drugs and a commitment to advance novel therapies" ^[3].

The purchase is small relative to Lilly's size. Cantor Fitzgerald analyst Carter Gould called $1.2 billion "borderline immaterial" to the company and said the lead program "would sit nicely within Lilly's cardiometabolic franchise" ^[1]. Lilly's market value topped $1 trillion in 2025 on surging sales of Mounjaro and Zepbound, and it lists 21 drugs in various stages of development in obesity and metabolic disease ^[1][2]. Its largest deal since 2018 remains the $8 billion purchase of cancer specialist Loxo Oncology ^[2].

Ventyx is not alone in the field. Novo Nordisk is testing NLRP3 inhibitors in Phase 1 for cardiovascular diseases, Roche has shown interest, and BioAge Labs, Neumora Therapeutics and NodThera have programs of their own, according to BioPharma Dive ^[2]. Stifel analyst Alex Thompson counted 17 programs and wrote that the deal validates the target while uncertainty remains about which diseases the drugs will ultimately treat ^[2].

Why it matters for patients

None of the Ventyx compounds are approved for sale, and no timeline for a launch has been disclosed. VTX3232 and the company's other candidates are in mid-stage testing, and Phase 2 results do not establish that a drug works or is safe ^[2][3]. The October findings came from a small study of people who were also taking semaglutide, so they do not show what the drug does on its own ^[2].

If such drugs eventually reach the market, they would be pills rather than injections, which could matter for people who dislike shots or want an alternative delivery method ^[2][3]. Much of the appeal for Lilly is pairing inflammation treatment with its existing metabolic medicines, because the October data looked at VTX3232 as an add-on to semaglutide ^[2]. Whether that combination is ever studied in a large trial, and in which patients, has not been reported.

The transaction does not change the availability, labeling or price of Mounjaro, Zepbound, Ozempic, Wegovy or Rybelsus. Lilly said it will determine the accounting treatment of the purchase at closing ^[3].

What happens next

The deal is expected to close in the first half of 2026, subject to approval by Ventyx stockholders and other customary conditions, including regulatory approvals ^[1][3]. Ventyx plans to file a proxy statement with the Securities and Exchange Commission, and affiliates of New Science Ventures plus all of Ventyx's directors and officers have signed voting agreements covering about 10% of its outstanding shares ^[3]. After closing, Ventyx's programs would be reflected in Lilly's financial results and guidance ^[3]. What Lilly plans to prioritize among the Ventyx candidates, and when later-stage trials might begin, has not been disclosed.